Arca
Skip to content
Tools
Tools

Label Changes: Azulfidine En-Tabs (sulfasalazine)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Azulfidine En-Tabs label DailyMed has published, from Pfizer Laboratories Div Pfizer Inc, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 26
  • Sections changed, version 34 to 35: 3

What changed from version 34 to version 35

Jun 1, 2026 to Oct 30, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. PrecautionsChanged ยท punctuation or symbols only
  2. Adverse reactionsChanged ยท 5 words added
  3. Untitled sectionChanged ยท 4 words added, 4 removed

Precautions

Changedpunctuation or symbols only
30 unchanged lines
No clinical studies have been performed to evaluate the effect of sulfasalazine on the growth development and functional maturation of children whose mothers received the drug during pregnancy.
Clinical Considerations
Sulfasalazine and its metabolite, sulfapyridine, pass through the placenta. Sulfasalazine and its metabolite are also present in human milk. In the newborn, sulfonamides compete with bilirubin for binding sites on the plasma proteins and may cause kernicterus. Although sulfapyridine has been shown to have poor bilirubin-displacing capacity, monitor the newborn for the potential for kernicterus.
8 unchanged lines

Adverse reactions

Changed5 words added
20 unchanged lines
Metabolism and nutrition system disorders: folate deficiency
Nervous system disorders: intracranial hypertension
Renal and urinary disorders: nephrolithiasis
3 unchanged lines

Untitled section

Changed4 words added, 4 removed
This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.
LAB-0237-1819.0
Revised: 4/2025
Revised: 9/2026

Unchanged: Untitled section, Description, Clinical pharmacology, Indications and usage, Contraindications, Warnings, Drug abuse and dependence, Overdosage, Dosage and administration, How supplied, References, PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label, PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label - NDC 0013-0102-50, PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Carton - NDC 0013-0102-50.

Every version

26 versions of set b9ef541a-93c8-4428-ba45-398aa0b327d1, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.